Literature DB >> 22652342

Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy.

Priyambada Parhi1, Chandana Mohanty, Sanjeeb Kumar Sahoo.   

Abstract

Combination therapy for the treatment of cancer is becoming more popular because it generates synergistic anticancer effects, reduces individual drug-related toxicity and suppresses multi-drug resistance through different mechanisms of action. In recent years, nanotechnology-based combination drug delivery to tumor tissues has emerged as an effective strategy by overcoming many biological, biophysical and biomedical barriers that the body stages against successful delivery of anticancer drugs. The sustained, controlled and targeted delivery of chemotherapeutic drugs in a combination approach enhanced therapeutic anticancer effects with reduced drug-associated side effects. In this article, we have reviewed the scope of various nanotechnology-based combination drug delivery approaches and also summarized the current perspective and challenges facing the successful treatment of cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22652342     DOI: 10.1016/j.drudis.2012.05.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  82 in total

1.  Development of genistein-PEGylated silica hybrid nanomaterials with enhanced antioxidant and antiproliferative properties on HT29 human colon cancer cells.

Authors:  Héctor Pool; Rocio Campos-Vega; María Guadalupe Herrera-Hernández; Pablo García-Solis; Teresa García-Gasca; Isaac Cornelius Sánchez; Gabriel Luna-Bárcenas; Haydé Vergara-Castañeda
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Nano-Co-Delivery of Berberine and Anticancer Drug Using PLGA Nanoparticles: Exploration of Better Anticancer Activity and In Vivo Kinetics.

Authors:  Iliyas Khan; Gaurav Joshi; Kartik T Nakhate; Raj Kumar; Umesh Gupta
Journal:  Pharm Res       Date:  2019-08-16       Impact factor: 4.200

Review 3.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.

Authors:  Raphaelle Fanciullino; Severine Mollard; Florian Correard; Sarah Giacometti; Cindy Serdjebi; Athanassios Iliadis; Joseph Ciccolini
Journal:  Pharm Res       Date:  2014-04-22       Impact factor: 4.200

5.  Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.

Authors:  Federico Perche; Niravkumar R Patel; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-09-10       Impact factor: 9.776

Review 6.  Bioavailability enhancers of herbal origin: an overview.

Authors:  Kritika Kesarwani; Rajiv Gupta; Alok Mukerjee
Journal:  Asian Pac J Trop Biomed       Date:  2013-04

Review 7.  The potential of magneto-electric nanocarriers for drug delivery.

Authors:  Ajeet Kaushik; Rahul Dev Jayant; Vidya Sagar; Madhavan Nair
Journal:  Expert Opin Drug Deliv       Date:  2014-07-02       Impact factor: 6.648

Review 8.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

9.  Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.

Authors:  Samuel V Mussi; Rupa Sawant; Federico Perche; Mônica C Oliveira; Ricardo B Azevedo; Lucas A M Ferreira; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

Review 10.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

Authors:  Claudia Corbo; Roberto Molinaro; Alessandro Parodi; Naama E Toledano Furman; Francesco Salvatore; Ennio Tasciotti
Journal:  Nanomedicine (Lond)       Date:  2015-12-11       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.